These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 11172805

  • 1. p-Hydroxyphenylacetaldehyde, the major product of tyrosine oxidation by the activated myeloperoxidase system can act as an antioxidant in LDL.
    Exner M, Alt E, Hermann M, Hofbauer R, Kapiotis S, Quehenberger P, Speiser W, Minar E, Gmeiner B.
    FEBS Lett; 2001 Feb 09; 490(1-2):28-31. PubMed ID: 11172805
    [Abstract] [Full Text] [Related]

  • 2. Thiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDL.
    Exner M, Hermann M, Hofbauer R, Hartmann B, Kapiotis S, Gmeiner B.
    Free Radic Biol Med; 2004 Jul 15; 37(2):146-55. PubMed ID: 15203186
    [Abstract] [Full Text] [Related]

  • 3. p-hydroxyphenylacetaldehyde, an aldehyde generated by myeloperoxidase, modifies phospholipid amino groups of low density lipoprotein in human atherosclerotic intima.
    Heller JI, Crowley JR, Hazen SL, Salvay DM, Wagner P, Pennathur S, Heinecke JW.
    J Biol Chem; 2000 Apr 07; 275(14):9957-62. PubMed ID: 10744670
    [Abstract] [Full Text] [Related]

  • 4. Copper- and magnesium protoporphyrin complexes inhibit oxidative modification of LDL induced by hemin, transition metal ions and tyrosyl radicals.
    Kapiotis S, Hermann M, Exner M, Laggner H, Gmeiner BM.
    Free Radic Res; 2005 Nov 07; 39(11):1193-202. PubMed ID: 16298745
    [Abstract] [Full Text] [Related]

  • 5. Products of the reaction of HOCl with tryptophan protect LDL from atherogenic modification.
    Kapiotis S, Jirovetz L, Hermann M, Laggner H, Exner M, Esterbauer H, Gmeiner BM.
    Biochimie; 2006 Jul 07; 88(7):785-91. PubMed ID: 16488068
    [Abstract] [Full Text] [Related]

  • 6. Human low density lipoprotein as a target of hypochlorite generated by myeloperoxidase.
    Jerlich A, Fabjan JS, Tschabuschnig S, Smirnova AV, Horakova L, Hayn M, Auer H, Guttenberger H, Leis HJ, Tatzber F, Waeg G, Schaur RJ.
    Free Radic Biol Med; 1998 May 07; 24(7-8):1139-48. PubMed ID: 9626568
    [Abstract] [Full Text] [Related]

  • 7. Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino-acid-derived aldehyde generated by myeloperoxidase, are present in human fatty streaks, intermediate lesions and advanced atherosclerotic lesions.
    Hazen SL, Gaut JP, Crowley JR, Hsu FF, Heinecke JW.
    Biochem J; 2000 Dec 15; 352 Pt 3(Pt 3):693-9. PubMed ID: 11104675
    [Abstract] [Full Text] [Related]

  • 8. Paracetamol catalyzes myeloperoxidase-initiated lipid oxidation in LDL.
    Kapiotis S, Sengoelge G, Hermann M, Held I, Seelos C, Gmeiner BM.
    Arterioscler Thromb Vasc Biol; 1997 Nov 15; 17(11):2855-60. PubMed ID: 9409266
    [Abstract] [Full Text] [Related]

  • 9. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
    Laggner H, Schreier S, Hermann M, Exner M, Mühl A, Gmeiner BM, Kapiotis S.
    Free Radic Res; 2007 Feb 15; 41(2):234-41. PubMed ID: 17364950
    [Abstract] [Full Text] [Related]

  • 10. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein.
    Savenkova ML, Mueller DM, Heinecke JW.
    J Biol Chem; 1994 Aug 12; 269(32):20394-400. PubMed ID: 8051134
    [Abstract] [Full Text] [Related]

  • 11. Ibuprofen protects low density lipoproteins against oxidative modification.
    Zapolska-Downar D, Zapolska-Downar A, Bukowska H, Gałka H, Naruszewicz M.
    Life Sci; 1999 Aug 12; 65(22):2289-303. PubMed ID: 10597884
    [Abstract] [Full Text] [Related]

  • 12. Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins.
    Hazell LJ, Davies MJ, Stocker R.
    Biochem J; 1999 May 01; 339 ( Pt 3)(Pt 3):489-95. PubMed ID: 10215584
    [Abstract] [Full Text] [Related]

  • 13. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima.
    Hazen SL, Heinecke JW.
    J Clin Invest; 1997 May 01; 99(9):2075-81. PubMed ID: 9151778
    [Abstract] [Full Text] [Related]

  • 14. Human neutrophils oxidize low-density lipoprotein by a hypochlorous acid-dependent mechanism: the role of vitamin C.
    Carr AC, Frei B.
    Biol Chem; 2002 May 01; 383(3-4):627-36. PubMed ID: 12033452
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins.
    Malle E, Waeg G, Schreiber R, Gröne EF, Sattler W, Gröne HJ.
    Eur J Biochem; 2000 Jul 01; 267(14):4495-503. PubMed ID: 10880973
    [Abstract] [Full Text] [Related]

  • 16. p-Hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies epsilon-amino groups of protein lysine residues.
    Hazen SL, Gaut JP, Hsu FF, Crowley JR, d'Avignon A, Heinecke JW.
    J Biol Chem; 1997 Jul 04; 272(27):16990-8. PubMed ID: 9202012
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes. A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase.
    Hazen SL, Hsu FF, Heinecke JW.
    J Biol Chem; 1996 Jan 26; 271(4):1861-7. PubMed ID: 8567631
    [Abstract] [Full Text] [Related]

  • 19. Salicylate promotes myeloperoxidase-initiated LDL oxidation: antagonization by its metabolite gentisic acid.
    Hermann M, Kapiotis S, Hofbauer R, Seelos C, Held I, Gmeiner B.
    Free Radic Biol Med; 1999 May 26; 26(9-10):1253-60. PubMed ID: 10381197
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.